Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: Participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation

Cancer Research

Volumn 70, Issue 11, 2010, Pages 4634-4643

  Harper, Kelly ^a   Arsenault, Dominique ^a   Boulay Jean, Stephanie ^a   Lauzier, Annie ^a   Lucien, Fabrice ^a   Dubois, Claire M ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPORTER; AUTOTAXIN; CYCLIC AMP; EXCHANGE PROTEIN DIRECTLY ACTIVATED BY CYCLIC AMP; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 4; RAC1 PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INVASION; CELL INVASION; CELL MATURATION; CELL TYPE; CONTROLLED STUDY; FEMALE; FIBROSARCOMA; HUMAN; HUMAN CELL; INVADOPODIA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 77953159888     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3813     Document Type: Article

References (50)

1. Stracke ML, Krutzsch HC, Unsworth EJ, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992;267:2524-2529
2. Kishi Y, Okudaira S, Tanaka M, et al. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 2006;281:17492-17500
3. Yang SY, Lee J, Park CG, et al. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis 2002;19:603-8.4.
4. Yang Y, Mou L, Liu N, Tsao MS. Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol 1999;21:216-222 (Pubitemid 129502219)
5. Tokumura A, Kume T, Fukuzawa K, et al. Peritoneal fluids from patients with certain gynecologic tumor contain elevated levels of bioactive lysophospholipase D activity. Life Sci 2007;80:1641-1649
6. Nochi H, Tomura H, Tobo M, et al. Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fluid of patients with rheumatoid arthritis in fibroblast-like synovial cells. J Immunol 2008;181:5111-5119
7. Sato K, Malchinkhuu E, Muraki T, et al. Identification of autotaxin as a neurite retraction-inducing factor of PC12 cells in cerebrospinal fluid and its possible sources. J Neurochem 2005;92:904-914
8. Mazereeuw-Hautier J, Gres S, Fanguin M, et al. Production of lysophosphatidic acid in blister fluid: involvement of a lysophospholipase D activity. J Invest Dermatol 2005;125:421-427
9. Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 2000;19:241-247 (Pubitemid 30077220)
10. Nam SW, Clair T, Kim YS, et al. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 2001;61: 6938-6944 (Pubitemid 32896522)
11. Umezu-Goto M, Kishi Y, Taira A, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002;158:227-233
12. van Meeteren LA, Ruurs P, Stortelers C, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 2006;26:5015-5022
13. Moolenaar WH, van Meeteren LA, Giepmans BN. The ins and outs of lysophosphatidic acid signaling. Bioessays 2004;26:870-881
14. Mills GB, Eder A, Fang X, et al. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res 2002;107:259-283
15. Brindley DN. Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer. J Cell Biochem 2004;92:900-912
16. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 2006;281:23589-23597
17. Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the edg family. J Biol Chem 2003;278:25600-25606
18. Tabata K, Baba K, Shiraishi A, Ito M, Fujita N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun 2007;363:861-866
19. van Leeuwen FN, Giepmans BN, van Meeteren LA, Moolenaar WH. Lysophosphatidic acid: mitogen and motility factor. Biochem Soc Trans 2003;31:1209-1212
20. Liu S, Umezu-Goto M, Murph M, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009;15:539-550
21. Zhang H, Xu X, Gajewiak J, et al. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res 2009;69:5441-5449
22. Yamaguchi H, Lorenz M, Kempiak S, et al. Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol 2005;168:441-452
23. Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nat Rev Cancer 2003;3:921-930 (Pubitemid 37500177)
24. Buccione R, Orth JD, McNiven MA. Foot and mouth: podosomes, invadopodia and circular dorsal ruffles. Nat Rev Mol Cell Biol 2004; 5:647-657
25. Yamaguchi H, Pixley F, Condeelis J. Invadopodia and podosomes in tumor invasion. Eur J Cell Biol 2006;85:213-218
26. Muralidharan-Chari V, Hoover H, Clancy J, et al. ADP-ribosylation factor 6 regulates tumorigenic and invasive properties in vivo. Cancer Res 2009;69:2201-2209
27. Alexander NR, Branch KM, Parekh A, et al. Extracellular matrix rigidity promotes invadopodia activity. Curr Biol 2008;18:1295-1299
28. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 2006;66:3034-3043
29. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. BioTechniques 1993;15:532-4, 536-537
30. Blanchette F, Rivard N, Rudd P, Grondin F, Attisano L, Dubois CM. Cross-talk between the p42/p44 MAP kinase and smad pathways in transforming growth factor β1-induced furin gene transactivation. J Biol Chem 2001;276:33986-33994
31. Baldassarre M, Ayala I, Beznoussenko G, et al. Actin dynamics at sites of extracellular matrix degradation. Eur J Cell Biol 2006;85: 1217-1231
32. Carragher NO, Walker SM, Scott Carragher LA, et al. Calpain 2 and Src dependence distinguishes mesenchymal and amoeboid modes of tumour cell invasion: a link to integrin function. Oncogene 2006; 25:5726-5740
33. Ishii S, Noguchi K, Yanagida K. Non-edg family lysophosphatidic acid (LPA) receptors. Prostaglandins Other Lipid Mediat 2009;89: 57-65.
34. Ganguly NK, Kaur T. Mechanism of action of cholera toxin & other toxins. Indian J Med Res 1996;104:28-37.
35. Cheng X, Ji Z, Tsalkova T, Mei F. Epac and PKA: a tale of two intracellular cAMP receptors. Acta Biochim Biophys Sin (Shanghai) 2008; 40:651-662
36. Hattori M, Minato N. Rap1 GTPase: functions, regulation, and malignancy. J Biochem 2003;134:479-484
37. Yamazaki D, Kurisu S, Takenawa T. Involvement of rac and rho signaling in cancer cell motility in 3D substrates. Oncogene 2009;28: 1570-1583
38. Hoshino D, Tomari T, Nagano M, et al. A novel protein associated with membrane-type 1 matrix metalloproteinase binds p27(kip1) and regulates RhoA activation, actin remodeling, and matrigel invasion. J Biol Chem 2009;284:27315-27326
39. Hama K, Aoki J, Fukaya M, et al. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 2004;279:17634-17639
40. Lee CW, Rivera R, Dubin AE, Chun J. LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated rho activation. J Biol Chem 2007; 282:4310-4317
41. Lee Z, Cheng CT, Zhang H, et al. Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell 2008;19:5435-5445
42. Taghavi P, Verhoeven E, Jacobs JJ, et al. In vitro genetic screen identifies a cooperative role for LPA signaling and c-myc in cell transformation. Oncogene 2008;27:6806-6816
43. Ishihara R, Tatsuta M, Iishi H, et al. Attenuation by cyclic phosphatidic acid of peritoneal metastasis of azoxymethane-induced intestinal cancers in Wistar rats. Int J Cancer 2004; 110:188-193
44. Willingham MC, Pastan I. Cyclic AMP modulates microvillus formation and agglutinability in transformed and normal mouse fibroblasts. Proc Natl Acad Sci U S A 1975;72:1263-1267
45. Bos JL. Linking rap to cell adhesion. Curr Opin Cell Biol 2005;17: 123-128
46. Mueller SC, Chen WT. Cellular invasion into matrix beads: localization of β1 integrins and fibronectin to the invadopodia. J Cell Sci 1991;99:213-225
47. Baumer Y, Drenckhahn D, Waschke J. cAMP induced rac 1-mediated cytoskeletal reorganization in microvascular endothelium. Histochem Cell Biol 2008;129:765-778
48. Ponsioen B, Gloerich M, Ritsma L, Rehmann H, Bos JL, Jalink K. Direct spatial control of Epac1 by cyclic AMP. Mol Cell Biol 2009; 29:2521-2531
49. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997;390:88-91.
50. Murph M, Mills GB. Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev Mol Med 2007;9:1-18.